Table 2.

Clinical features between two subgroups with different evolution of autoantibodies

	Auto-Ab(+) subgroup at follow-up, n = 16	Auto-Ab(-) subgroup at follow-up, n = 11	p
Female, n (%)	9 (56.3)	5 (45.5)	0.704
Age, y, median (IQR)	61 (58–68)	62 (41–66)	0.521
Concomitant autoimmune diseases, n (%)	5 (31.3)	3 (27.3)	0.100
Baseline parameters, median (IQR)
ALT, ×ULN	32.6 (23.1–42.7)	30.9 (19.6–48.8)	0.961
AST, ×ULN	33.0 (18.6–43.5)	43.0 (16.8–52.2)	0.730
ALP, ×ULN	1.6 (1.4–1.7)	1.5 (1.4–2.1)	0.882
GGT, ×ULN	3.1 (1.9–4.4)	3.1 (2.2–4.2)	0.554
Total bilirubin, ×ULN	6.5 (5.4–9.2)	10.0 (3.7–12.7)	0.554
INR	1.02 (0.95–1.16)	1.03 (0.95–1.14)	0.586
Serum IgG, mg/dL	1550 (1255–1645)	1440 (1290–1575)	0.748
Serum IgA, mg/dL	304 (267–346)	302 (211–355)	0.537
Serum IgM, mg/dL	239 (175–269)	325 (158–356)	0.622
Serum IgE, IU/mL	39 (17–103)	127 (66–225)	0.046
Follow-up parameters, median (IQR)
ALT, ×ULN	0.3 (0.2–0.4)	0.3 (0.2–0.3)	0.334
AST, ×ULN	0.6 (0.5–0.6)	0.5 (0.5–0.6)	0.308
ALP, ×ULN	0.6 (0.5–0.8)	0.6 (0.5–0.9)	0.980
GGT, ×ULN	0.3 (0.2–0.4)	0.6 (0.3–0.7)	0.108
Total bilirubin, ×ULN	0.7 (0.6–0.8)	0.8 (0.7–0.9)	0.570

HEV hepatitis E virus, IQR interquartile range, ALT alanine aminotransferase, ULN upper limit of normal, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transpeptidase, INR International Normalized Ratio, Ig immunoglobulin